Robert Baffi - 16 Jan 2024 Form 4 Insider Report for Neurogene Inc. (NGNE)

Reporting relationship: Director
Issuer ticker: NGNE
Reported as of: 16 Jan 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jan 2024, 18:51:00 UTC
Prior SEC filing: 26 Dec 2023
Next SEC filing: 17 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Christine Mikail, as attorney-in-fact for Robert Baffi

Key filing fact

Robert Baffi filed Form 4 for Neurogene Inc. (NGNE) on 18 Jan 2024.

Key facts

This page summarizes Robert Baffi's Form 4 filing for Neurogene Inc. (NGNE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Jan 2024, 18:51.

Change

Previous filing in this sequence was filed on 26 Dec 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NGNE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +15,400
Change %
Price: $0.000000
Shares after: 15,400
Date: 16 Jan 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,400
Exercise price: $32.30
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents the right to purchase 15,400 shares of common stock of the Issuer, and vests in equal monthly installments through January 16, 2027, subject to the reporting person's continued service to the Issuer through each applicable vesting date.